The partnership combines the world-leading expertise and technology of the Professor Alessio Ciulli laboratory in PROTACs research, with Eisais discovery researches and clinical development experiences in oncology area. It will also focus on findings of target protein degradation based on Eisais basic research, to aim to create innovative new drugs. PROTACs consist of two covalently linked protein-binding molecules: one capable of engaging an ubiquitin ligase, and another that binds to a target protein meant for degradation. The partners hope that research into PROTACs will lead to new drug discoveries for proteins present in cancer, which are difficult to treat with conventional small molecule inhibitors. In this collaboration research, Professor Alessio Ciulli, one of the global pioneers in the field of PROTACs research, at the School of Life Sciences, University of Dundee is responsible for directing the research.